In this CE Concepts livestream symposium, expert faculty will guide learners to identify features and challenges of early diagnosis and treatment of DTs, evaluate the use of novel targeted therapies, and implement evidence-based strategies to monitor and manage AEs associated with systemic therapies for DTs to improve patient safety and adherence.
In this CE Concepts recorded webcast, expert faculty will discuss utilizing biomarker tests to select therapeutic approaches for patients with upper GI cancers, implementing current guidelines and recent clinical evidence to individualize treatment, and integrating an MDT approach to deliver high-quality disease management.
In this enduring CEC ONS Chapter installment, expert faculty will review emerging data on ADC use for HER2-neg MBC and share insights and strategies on the impact of AEs associated with ADC use and approaches to the management of AEs associated with ADCs in this patient population.
In this CEC Oncology recorded, case-based symposium, expert faculty will discuss diagnosis and disease challenges over a person’s lifespan; explore the integration of MEK inhibitors in the management of NF1-associated PNs in pediatric patients; and consider comprehensive interprofessional care plans that include disease monitoring, toxicity management, and individualizing disease treatment across the patient’s lifespan.
In this CE Concepts live webcast, expert faculty will discuss utilizing biomarker tests to select therapeutic approaches for patients with upper GI cancers, implementing current guidelines and recent clinical evidence to individualize treatment, and integrating an MDT approach to deliver high-quality disease management.
In this CE Concepts webcast, expert faculty will guide learners on how to best evaluate the effect of CAR T-cell and bispecific antibody therapies on the immune system in patients with cancer, utilize best practices for the diagnosis and management of patients receiving T-cell-directing therapies experiencing symptoms consistent with CRS, and Integrate best practices for diagnostic and management approaches for patients receiving T-cell-directing therapies experiencing AEs not consistent with CRS.
